Vincerx Pharma Announces FDA Clearance of IND for VIP943
August 22, 2023 07:30 ET
|
Vincerx Pharma, Inc.
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx’s development...
Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 07, 2023 09:25 ET
|
Vincerx Pharma, Inc.
IND Application filed for potential best-in-class ADC, VIP943; Phase 1 trial expected to begin Q4 2023 Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class SMDC ...
Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 16:05 ET
|
Vincerx Pharma, Inc.
Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class αvβ3 small molecule drug conjugate (SMDC) for the treatment of solid tumors IND filing for VIP943, a next-generation...
Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting
April 19, 2023 09:05 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023
April 17, 2023 13:35 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting
April 17, 2023 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
March 28, 2023 16:05 ET
|
Vincerx Pharma, Inc.
First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an αvβ3 small molecule drug conjugate (SMDC) in advanced solid tumors IND filing for antibody drug conjugate...
Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023 16:35 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference
February 06, 2023 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236
December 13, 2022 09:29 ET
|
Vincerx Pharma, Inc.
VIP236 is a first-in-class αVβ3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications Preclinical studies with VIP236 demonstrated...